In Hormone-Receptor-positive (HR+) breast cancer, representing approximately 70% of cases, acquired resistance can be monitored using LB targeted to mutations occurring within the Ligand-Binding Domain (LBD) of the Estrogen Receptor-1 (ESR1) gene [102]. This evidence concerns the gene ESR1 and breast cancer.